



WOMEN

FIRST CANCER SITE  
**CORPUS UTERI**

**CORPUS UTERI**  
**POOL AIRTUM 1976-2010, WOMEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**CORPO DELL'UTERO**  
**POOL AIRTUM 1976-2010, DONNE:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	34142		35497		35497		34142		29060		15406		7339		34142	35497
Person-years ▶	201942		207744		5802		26265		84671		55061		35945		201942	207744
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND CORPUS UTERI	2614	1.23	2821	1.29	207	3.77	315	1.27	1072	1.29	706	1.18	521	1.16	2.41	3.07
HEAD AND NECK	20	0.69	21	0.71	1	1.33	5	1.46	9	0.78	4	0.49	2	0.34	-0.04	-0.04
ORAL CAVITY	10	0.66	10	0.64	0	0.00	2	1.15	6	1.02	1	0.23	1	0.30	-0.03	-0.03
PHARYNX	4	0.62	5	0.75	1	5.60	1	1.23	2	0.75	1	0.55	0	0.00	-0.01	-0.01
LARYNX	6	0.83	6	0.81	0	0.00	2	2.28	1	0.34	2	0.99	1	0.71	-0.01	-0.01
OESOPHAGUS	6	0.58	6	0.56	0	0.00	1	0.85	3	0.76	2	0.68	0	0.00	-0.02	-0.02
STOMACH	126	1.02	127	1.00	1	0.31	9	0.62	49	1.03	32	0.92	36	1.34	0.01	0.00
COLON RECTUM	458	1.35	481	1.38	23	2.70	40	1.04	196	1.51	131	1.36	91	1.21	0.58	0.64
COLON	326	1.34	340	1.36	14	2.32	26	0.95	147	1.59	91	1.32	62	1.14	0.41	0.44
RECTUM	132	1.37	141	1.42	9	3.61	14	1.24	49	1.30	40	1.47	29	1.41	0.17	0.20
LIVER	48	0.82	50	0.83	2	1.37	3	0.46	19	0.86	15	0.91	11	0.81	-0.05	-0.05
GALLBLADDER	42	0.91	42	0.89	0	0.00	2	0.38	17	0.97	9	0.70	14	1.36	-0.02	-0.03
PANCREAS	92	1.07	92	1.04	0	0.00	4	0.43	34	1.07	25	1.02	29	1.41	0.03	0.02
LUNG	220	1.55	234	1.61	14	4.06	10	0.64	105	1.95	60	1.49	45	1.41	0.39	0.43
SKIN MELANOMA	58	1.43	61	1.46	3	2.82	7	1.44	18	1.10	16	1.41	17	2.11	0.09	0.09
MESOTHELIOMA	9	1.48	9	1.45	0	0.00	1	1.51	5	2.18	2	1.16	1	0.72	0.01	0.01
KAPOSI SARCOMA	2	0.70	2	0.68	0	0.00	1	3.10	1	0.94	0	0.00	0	0.00	0.00	0.00
SOFT TISSUE	18	1.96	18	1.91	0	0.00	0	0.00	7	1.93	6	2.34	5	2.61	0.04	0.04
BONE	4	1.59	4	1.55	0	0.00	2	6.49	0	0.00	2	2.85	0	0.00	0.01	0.01
BREAST	841	1.44	884	1.48	43	2.74	117	1.64	341	1.44	231	1.42	152	1.36	1.28	1.38
CERVIX UTERI	8	0.27	20	0.65	12	13.33	4	0.99	3	0.23	1	0.12	0	0.00	-0.11	-0.05
CORPUS UTERI	0	0.00	13	0.11	13	4.33	0	0.00	0	0.00	0	0.00	0	0.00	-0.55	-0.48
OVARY	45	0.63	109	1.48	64	32.99	26	2.96	12	0.41	4	0.20	3	0.22	-0.13	0.17
KIDNEY AND RENAL PELVIS	93	1.71	108	1.93	15	11.20	24	3.93	39	1.86	17	1.09	13	1.09	0.19	0.25
BLADDER AND URINARY TRACT	98	1.18	107	1.26	9	4.41	9	0.97	48	1.53	21	0.89	20	1.07	0.08	0.11
URINARY BLADDER	93	1.21	102	1.29	9	4.72	8	0.93	44	1.51	21	0.96	20	1.15	0.08	0.11
URINARY TRACT	5	0.88	5	0.86	0	0.00	1	1.65	4	1.92	0	0.00	0	0.00	0.00	0.00
BRAIN AND CENTRAL NERVOUS SYSTEM	41	1.23	43	1.26	2	2.31	4	1.02	14	1.06	14	1.49	9	1.30	0.04	0.04
THYROID	52	1.26	53	1.25	1	0.87	9	1.72	27	1.56	11	0.97	5	0.70	0.05	0.05
HODGKIN LYMPHOMA	9	1.75	9	1.70	0	0.00	0	0.00	5	2.33	3	2.14	1	1.08	0.02	0.02
NON-HODGKIN LYMPHOMA	90	1.07	93	1.08	3	1.42	10	1.04	29	0.89	29	1.22	22	1.23	0.03	0.03
MYELOMA	39	1.01	40	1.01	1	1.03	2	0.45	12	0.81	14	1.29	11	1.30	0.00	0.00
LEUKAEMIAS	64	1.20	65	1.19	1	0.73	5	0.81	27	1.32	24	1.60	8	0.68	0.05	0.05
LYMPHOID LEUKAEMIAS	19	0.80	20	0.83	1	1.63	2	0.72	7	0.76	5	0.75	5	0.99	-0.02	-0.02
MYELOID LEUKAEMIAS	39	1.54	39	1.50	0	0.00	3	1.04	18	1.85	16	2.24	2	0.35	0.07	0.06
OTHER LEUKAEMIAS	6	1.39	6	1.36	0	0.00	0	0.00	2	1.23	3	2.49	1	1.01	0.01	0.01
OTHER AND ILL DEFINED SITES	131	0.85	143	0.90	12	3.12	20	1.15	52	0.90	33	0.76	26	0.73	-0.11	-0.07

■ Decrease/Difetto    ○ Observed cases    ■ SIR Standardized Incidence Ratio    ■ EAR Excess Absolute Risk  
■ Increase/Eccesso    ○ Casi osservati    ■ Rapporto standardizzato di incidenza    ■ Eccesso assoluto di rischio